spliceswitch
oligonucleotid
sso
current
promis
therapeut
use
duchenn
muscular
dystrophi
dmd
exon
skip
spinal
muscular
atrophi
sma
promot
exon
inclus
sso
design
steric
block
splice
site
specif
bind
motif
splice
machineri
order
promot
exon
inclus
exclus
dmd
target
dystrophin
premrna
sso
use
skip
exon
contain
nonsens
code
mutat
remov
exon
neighbour
outoffram
genom
delet
restor
mrna
read
frame
allow
synthesi
intern
delet
dystrophin
protein
retain
element
crucial
function
proofofprincipl
approach
demonstr
murin
canin
anim
model
dmd
recent
human
phase
iiiii
clinic
trial
variou
sso
chemistri
develop
exon
skip
includ
phosphorodiamid
morpholino
oligonucleotid
pmo
peptid
nucleic
acid
pna
lock
nucleic
acid
lna
phosphorothio
oligonucleotid
phosphorothio
oligonucleotid
tricyclo
oligonucleotid
see
recent
review
two
major
sso
chemistri
use
extens
current
clinic
trial
dmd
patient
pmo
trial
product
dystrophin
protein
demonstr
albeit
low
level
rather
disappointingli
recent
phase
iii
trial
sso
abl
meet
primari
endpoint
statist
signific
improv
min
walk
test
nevertheless
preliminari
result
pmo
chemistri
promis
studi
plan
target
addit
exon
date
clinic
trial
focus
target
remov
exon
sinc
would
benefit
largest
patient
pool
sso
also
develop
target
exon
signific
barrier
success
spliceswitch
therapi
effect
deliveri
case
pmo
inde
chemistri
level
exon
skip
henc
amount
function
dystrophin
restor
muscl
poor
unless
high
dose
use
thought
due
mostli
rapid
clearanc
bodi
follow
system
administr
well
poor
abil
penetr
cellular
barrier
reach
nuclear
target
site
one
approach
address
attach
cellpenetr
peptid
cpp
effect
carri
charg
neutral
pmo
cargo
across
cell
membran
premrna
target
site
nucleu
particular
pmo
conjug
argininerich
cpp
known
ppmo
shown
enhanc
dystrophin
product
muscl
follow
system
administr
mdx
mous
model
dmd
previous
develop
seri
novel
argininerich
cpp
known
pnapmo
intern
peptid
pip
compris
two
argininerich
sequenc
separ
central
short
hydrophob
core
sequenc
pip
peptid
design
improv
serum
stabil
whilst
maintain
high
level
exon
skip
initi
attach
pna
cargo
deriv
peptid
design
conjug
pmo
shown
lead
high
bodywid
skelet
muscl
dystrophin
product
importantli
also
includ
heart
follow
system
administr
later
version
prove
even
effici
conjug
mediat
dystrophin
product
mdx
mous
whilst
restor
absent
dystrophin
protein
primari
goal
genet
therapi
dmd
consider
complementari
therapi
reduc
patholog
featur
diseas
improv
muscl
function
also
import
one
strategi
would
promot
muscl
growth
target
myostatin
pathway
myostatin
growthdifferenti
member
transform
growth
famili
involv
muscl
homeostasi
act
inhibit
muscl
growth
myostatin
involv
control
myogenesi
bind
activin
type
iib
receptor
acvriib
recruit
activ
activin
type
receptor
activin
receptor
activ
result
phosphoryl
intracellular
signal
mediat
transloc
nucleu
affect
gene
transcript
evid
inhibit
myostatin
pathway
potenti
clinic
benefit
dmd
transgen
knockout
model
myostatin
dystrophin
demonstr
increas
musculatur
due
fibr
hypertrophi
well
reduc
fibrosi
fat
deposit
compar
mdx
mice
alon
similarli
mdx
mice
treat
antimyostatin
antibodi
result
enlarg
muscl
concurr
improv
muscl
function
strong
reduct
diaphragm
fibrosi
base
improv
muscl
featur
concept
myostatin
downregul
concurr
dystrophin
restor
investig
dumonceaux
et
al
report
use
adenoassoci
viru
aav
construct
combin
rnaimedi
downregul
acvriib
small
rna
exon
skip
techniqu
restor
dystrophin
whilst
concurr
treatment
improv
muscl
mass
absolut
specif
forc
much
greater
compar
either
individu
strategi
subsequ
studi
hoogaar
et
al
util
solubl
acvriib
decoy
receptor
combin
mediat
dystrophin
restor
treat
mdx
mice
treatment
decoy
acvriib
increas
bodi
weight
morphometr
measur
muscl
fibr
suggest
muscl
growth
due
hypertrophi
base
potenti
success
approach
sought
simultan
target
dystrophin
myostatin
pathway
molecular
model
evalu
efficaci
use
bispecif
pmo
compound
spliceswitch
approach
use
previous
target
downregul
express
myostatin
pathway
sso
develop
target
mstn
transcript
whilst
principl
multipleexon
target
dystrophin
restor
myostatin
deplet
demonstr
use
cocktail
individu
sso
advantag
develop
bispecif
compound
target
two
premrna
first
outcom
use
bispecif
sso
sso
must
enter
cell
wherea
cocktail
sso
like
mix
popul
cell
either
none
one
gene
target
importantli
sinc
cell
vivo
toxic
ppmo
thought
predominantli
due
peptid
use
singl
peptid
deliv
pmo
halv
total
peptid
requir
compar
use
cocktail
two
separ
ppmo
may
help
reduc
potenti
peptidemedi
toxic
note
also
two
sso
target
dystrophin
myostatin
join
togeth
recent
make
bispecif
construct
without
attach
deliveri
peptid
case
activ
mdx
mice
seen
dystrophin
sso
studi
select
cpp
simultan
deliv
two
differ
pmo
bispecif
conjug
develop
chemistri
attach
three
differ
conjug
chemistri
includ
amid
disulfid
triazol
bond
util
allow
orthogon
conjug
first
pmo
target
exon
dystrophin
gene
correct
mdx
genotyp
second
target
remov
exon
gene
produc
intern
delet
protein
lack
crucial
transmembran
domain
sever
differ
bispecif
conjug
design
investig
wherebi
two
pmo
join
either
one
end
peptid
one
pmo
either
n
ctermini
activ
conjug
construct
assess
mous
mdx
cell
activ
bispecif
conjug
pmo
attach
cterminu
cpp
shown
close
compar
dmd
exon
skip
activ
singl
target
dmd
conjug
also
assess
cell
target
conjug
demonstr
slightli
reduc
exon
skip
activ
compar
target
importantli
cell
viabil
use
bispecif
compound
significantli
better
mixtur
two
individu
furthermor
assess
potenti
approach
vivo
environ
intramuscular
administr
demonstr
signific
differ
exon
skip
activ
dmd
target
bispecif
conjug
cocktail
individu
ppmo
equival
fmocprotect
amino
acid
coupl
reagent
hbtu
pybop
preload
wang
resin
mmol
obtain
merck
hohenbrunn
germani
fmocazidollysineoh
iri
biotech
gmbh
deutschland
germani
fmoclbishomopropargylglycineoh
bpg
purchas
chiralix
nijmegen
netherland
chicken
embryo
extract
cee
hors
serum
hs
cell
cultur
obtain
sera
laboratori
intern
ltd
west
sussex
uk
obtain
roch
appli
scienc
penzberg
germani
reagent
obtain
st
loui
mo
usa
unless
otherwis
state
malditof
mass
spectrometri
tabl
carri
use
voyag
de
pro
biospectrometri
workstat
stock
solut
mg
acid
sinapin
acid
acetonitril
water
use
matrix
measur
accuraci
level
peptid
synthes
standard
fmoc
chemistri
use
cem
microwav
peptid
synthes
buckingham
uk
peptid
assembl
preload
wang
resin
mmol
scale
excess
fmocprotect
amino
acid
pybop
dipea
protect
group
remov
treat
resin
piperidin
dmf
vv
twice
min
coupl
reaction
carri
min
order
prevent
racem
fmoccystein
trt
oh
coupl
min
w
microwav
power
amino
acid
singl
coupl
except
arginin
doubl
coupl
fmoclbishomopropargylglycineoh
coupl
manual
use
excess
coupl
success
check
use
tnb
test
complet
peptid
assembl
resin
bound
peptid
cleav
treat
resin
cocktail
tfa
dodt
tip
vvvv
h
peptid
precipit
addit
icecold
diethyl
ether
wash
three
time
crude
peptid
analys
purifi
reversedphas
hplc
rphplc
peptid
mass
character
carri
use
malditof
mass
spectrometri
abi
voyag
de
pro
acid
matrix
made
acetonitril
contain
tfa
pmo
sequenc
exon
skip
dmd
premrna
either
unmodifi
standard
morpholino
secondari
amin
end
function
disulfid
pmo
target
unmodifi
pmo
purchas
gene
tool
llc
philomath
usa
pmo
function
azido
group
coupl
free
amin
group
fmocazidollysineoh
figur
coupl
carri
activ
carboxyl
group
amino
acid
deriv
use
hbtu
eq
hoat
eq
nmp
presenc
eq
diea
addit
pmo
dissolv
dimethylsulfoxid
dmso
conjug
purifi
use
rphplc
follow
fmoc
deprotect
purif
case
pmo
disulfid
bond
end
figur
disulfid
bond
reduc
give
free
sulfhydryl
group
use
excess
tri
phosphin
hydrochlorid
water
h
follow
filtrat
remov
excess
tcep
pmo
free
sulfhydryl
group
activ
use
molar
excess
dtnp
dmso
acetonitril
tfa
tfa
ratio
reaction
mixtur
stir
room
temperatur
h
npysactiv
pmo
purifi
rphplc
conjug
peptid
pmo
figur
carri
solut
use
excess
peptid
use
similar
condit
coupl
fmocazidollysineoh
pmo
conjug
second
pmo
carri
use
either
copper
mediat
alkyneazid
click
chemistri
alkynefunction
ppmo
figur
azidefunction
second
pmo
form
disulfid
bond
npysactiv
second
pmo
free
cystein
thiol
ppmo
figur
alkyneazid
click
reaction
azidefunction
pmo
alkyn
function
ppmo
carri
dissolv
ppmo
water
follow
addit
azidofunction
pmo
eq
sodium
ascorb
eq
solut
ad
reaction
mixtur
vortex
thoroughli
follow
addit
copper
ii
tbta
eq
mm
solut
click
reaction
carri
room
temperatur
min
conjug
npysactiv
pmo
ppmo
carri
first
dissolv
npysactiv
pmo
ammonium
bicarbon
solut
ph
follow
addit
ppmo
dissolv
water
reaction
mixtur
stir
room
temperatur
h
singl
dual
ppmo
conjug
purifi
highresolut
hr
cationexchang
column
ge
healthcar
usa
use
mm
sodium
phosphat
buffer
ph
contain
acetonitril
conjug
elut
use
nacl
solut
buffer
flow
rate
ml
excess
salt
remov
centrifug
use
centrifug
filter
devic
conjug
character
use
malditof
ms
mention
dissolv
steril
water
filter
cellulos
acet
membran
costar
use
mous
myoblast
plate
densiti
cell
per
well
gelatin
precoat
plate
myoblast
grown
highglucos
dulbecco
modifi
eagl
medium
dmem
supplement
foetal
calf
serum
fc
cee
myoblast
cell
differenti
myotub
exonskip
assay
myoblast
differenti
day
dmem
supplement
hs
prior
transfect
ppmo
serumfre
optimem
h
transfect
medium
replac
hs
cell
incub
h
experi
carri
biomed
scienc
unit
univers
oxford
accord
procedur
author
uk
home
offic
experi
carri
mdx
mice
intramuscular
im
inject
n
per
treatment
carri
mdx
mice
gener
anaesthesia
nmol
salin
volum
inject
tibiali
anterior
ta
muscl
two
week
postadministr
anim
sacrif
rise
inhal
tissu
snapfrozen
dri
ice
cool
isopentan
bath
store
rna
extract
either
cell
pellet
ta
tissu
section
mechan
disrupt
subsequ
process
use
trizol
accord
manufactur
instruct
life
technolog
rtpcr
analysi
exon
skip
level
carri
ng
total
rna
use
templat
rtpcr
use
geneamp
rna
pcr
kit
appli
biosystem
warrington
uk
rtpcr
amplif
dystrophin
dmd
transcript
carri
follow
condit
cycl
use
follow
primer
two
microlitr
reaction
use
templat
nest
amplif
use
amplitaq
gold
appli
biosystem
warrington
uk
follow
condit
cycl
use
follow
primer
rtpcr
amplif
carri
follow
condit
cycl
use
follow
primer
pcr
product
analys
agaros
gel
quantit
analysi
exon
skip
level
rna
revers
transcrib
use
high
capac
cdna
rt
kit
appli
biosystem
warrington
uk
accord
manufactur
instruct
qpcr
analysi
carri
use
ng
cdna
templat
amplifi
taqman
gene
express
master
mix
appli
biosystem
warrington
uk
stepon
plu
thermocycl
appli
biosystem
warrington
uk
level
dmd
exon
skip
determin
multiplex
qpcr
famlabel
primer
span
exon
assay
mm
integr
dna
technolog
leuven
belgium
hexlabel
primer
span
exon
integr
dna
technolog
leuven
belgium
percentag
dmd
transcript
skip
exon
determin
normal
dmd
exon
amplif
level
dmd
exon
level
level
exon
skip
determin
qpcr
use
famlabel
primer
span
exon
integr
dna
technolog
leuven
belgium
normal
cyclophilin
b
housekeep
gene
appli
biosystem
warrington
uk
level
cytotox
ppmo
assess
human
hepatocyt
cell
incub
cell
ppmo
dual
dmd
combin
treatment
dmd
cell
grown
confluenc
fc
plate
ppmo
made
optimem
without
serum
cell
treat
h
optimem
remov
fresh
fc
ad
cell
incub
h
follow
addit
celltit
aqueou
one
solut
reagent
promega
southampton
uk
level
cell
viabil
determin
case
measur
absorb
nm
novel
bispecif
pmo
compound
develop
involv
use
standard
peptid
synthesi
method
synthesi
function
peptid
compon
pmo
compon
obtain
use
initi
unmodifi
pmo
function
azido
group
figur
enabl
click
conjug
altern
function
pmo
use
prepar
pmo
figur
yield
pmo
wherea
pmo
lower
yield
twostep
rphplc
purif
use
cpp
chosen
construct
figur
two
differ
type
bispecif
compound
design
first
two
pmo
oligonucleotid
conjug
differ
end
peptid
figur
design
second
pmo
oligonucleotid
attach
carboxytermin
end
design
case
click
chemistri
conjug
pmo
synthes
alkyn
group
either
nterminu
cterminu
figur
pmo
dmd
conjug
cterminu
amid
bond
conjug
nterminu
triazol
bond
bispecif
conjug
pmo
click
conjug
wherea
conjug
dmd
target
pmo
click
conjug
click
conjug
cterminu
one
b
one
aminohexano
acid
x
spacer
residu
incorpor
either
side
bpg
alkyn
deriv
wherea
spacer
use
ntermin
click
conjug
figur
bispecif
conjug
prepar
similar
space
disulfid
bond
replac
triazol
bond
synthesi
ctermin
xcysb
extens
figur
assembl
bispecif
conjug
requir
synthesi
three
differ
deriv
synthes
solid
phase
use
fmoc
peptid
chemistri
purifi
rphplc
puriti
yield
construct
conjug
first
pmo
three
deriv
carri
amid
bond
format
ctermin
carboxyl
acid
group
peptid
secondari
amin
pmo
similarli
synthesi
dmd
figur
b
conjug
carri
solut
purif
carri
ion
exchang
hplc
isol
yield
ppmo
base
amount
start
pmo
pmo
coupl
alkyneppmo
use
copper
mediat
alkyneazid
click
chemistri
result
yield
conjug
conjug
figur
click
reaction
synthes
sluggish
room
temperatur
h
small
amount
bispecif
conjug
form
figur
howev
heat
reaction
mixtur
significantli
improv
reaction
rate
min
reaction
proceed
near
complet
determin
ion
exchang
hplc
figur
pmo
dmd
conjug
ppmo
give
disulfid
bond
bispecif
conjug
figur
yield
mass
spectral
character
conjug
intermedi
shown
tabl
efficaci
bispecif
ppmo
construct
assess
initi
screen
step
rtpcr
use
dmd
exon
skip
mdx
cell
figur
conjug
test
high
level
exon
skip
found
dosedepend
manner
exon
doubl
skip
frequent
observ
test
system
bispecif
conjug
pmo
conjug
cterminu
exhibit
better
exonskip
activ
sinc
bispecif
conjug
less
effect
suggest
advantag
use
cleavabl
disulfid
linkag
use
stabl
click
chemistri
addit
second
pmo
control
singli
conjug
dmd
demonstr
slightli
higher
exon
skip
compar
conjug
bispecif
conjug
show
best
dmd
exon
skip
level
examin
exonskip
efficaci
figur
result
mirror
dmd
target
slightli
higher
exon
skip
observ
control
singli
conjug
compar
bispecif
counterpart
addit
gener
level
exon
skip
gene
found
lower
dmd
potenti
disrupt
exon
skip
oligonucleotid
gene
harder
achiev
skip
dmd
exon
fulli
optim
yet
bispecif
conjug
margin
effici
sinc
conjug
demonstr
skip
activ
gene
cell
highest
level
dmd
exon
skip
evalu
vivo
mdx
mous
model
dmd
intramuscular
administr
nmol
either
bispecif
conjug
carri
ta
muscl
mdx
mice
compar
molar
cocktail
singli
conjug
analysi
spliceswitch
activ
carri
week
postadministr
conjug
demonstr
robust
spliceswitch
activ
higher
spliceswitch
activ
evid
dmd
target
compar
also
seen
vitro
cell
cultur
studi
sinc
signific
differ
construct
could
seen
follow
gel
analysi
rtpcr
case
dmd
gene
target
figur
quantit
analysi
splice
switch
carri
use
qpcr
primer
determin
reduct
level
transcript
contain
target
exon
case
exon
skip
dmd
transcript
found
normal
dmd
transcript
noninject
control
muscl
statist
signific
differ
seen
ppmo
treat
mice
singli
conjug
bispecif
conjug
unsurprisingli
pattern
exon
skip
also
maintain
gene
target
signific
differ
seen
conjug
singli
conjug
counterpart
figur
cell
vivo
toxic
ppmo
known
predominantli
function
peptid
compon
dosedepend
therefor
cell
viabil
bispecif
conjug
assess
human
hepatocyt
cell
compar
dmd
mixtur
two
two
differ
target
dmd
case
use
high
equimolar
concentr
base
total
pmo
thu
bispecif
conjug
compar
mixtur
dmd
percentag
cell
surviv
measur
figur
result
show
significantli
higher
cell
viabil
bispecif
conjug
compar
mixtur
two
individu
target
promis
sso
therapeut
agent
realiz
number
clinic
trial
dmd
progress
assess
efficaci
target
singl
exon
exon
bypass
diseas
caus
mutat
clinic
trial
also
undertaken
target
exon
notabl
region
cover
exon
multipl
simultan
exon
skip
use
cocktail
sso
suggest
approach
target
major
patient
proofofconcept
multipl
exon
skip
demonstr
golden
retriev
model
dmd
well
human
patient
cell
line
concept
extend
target
exon
use
cocktail
variou
sso
unsurprisingli
level
exon
skip
found
date
low
attempt
improv
efficaci
studi
undertaken
mous
model
use
cocktail
differ
vivomorpholino
pmo
delet
entir
stretch
exon
although
skip
transcript
could
detect
mice
signific
like
toxic
deliv
mice
individu
pmo
function
guanidinium
group
might
hinder
clinic
develop
instead
use
cocktail
ppmo
need
mind
minim
toxic
sought
develop
proofofconcept
use
bispecif
pmo
sso
could
simultan
target
two
differ
exon
differ
gene
rather
gene
chose
initi
studi
simultan
target
exon
dmd
gene
exon
gene
use
singl
cpp
pmo
deliveri
agent
observ
whether
exon
skip
could
maintain
target
dumonceaux
et
al
show
combin
restor
dystrophin
simultan
inhibit
myostatinsignal
pathway
result
signific
improv
muscl
growth
forc
dystroph
mdx
mice
similar
studi
myostatin
knockdown
conjunct
dystrophin
restor
use
exonskip
approach
use
cocktail
two
separ
result
significantli
increas
mous
muscl
mass
thu
target
two
gene
way
might
expect
clinic
relev
use
wellcharacter
argrich
cpp
model
cpp
known
high
level
exon
skip
observ
pmo
conjug
dmd
model
design
orthogon
conjug
chemistri
use
amid
disulfid
triazol
bond
first
conjug
pmo
carri
case
format
stabl
amid
bond
amin
pmo
ctermin
carboxyl
group
synthet
deriv
second
pmo
conjug
effect
either
use
alkyn
group
azidefunction
pmo
give
stabl
triazol
linkag
cy
residu
activ
thiol
group
pmo
form
revers
disulfid
linkag
figur
bispecif
conjug
one
pmo
terminu
whilst
pmo
cterminu
sluggish
click
conjug
second
pmo
cterminu
room
temperatur
presum
due
poorer
access
case
heat
readili
facilit
triazol
bond
format
figur
conjug
second
pmo
use
disulfid
bond
requir
heat
mdx
muscl
cell
lowest
exonskip
efficaci
observ
bispecif
conjug
pmo
conjug
end
suggest
abil
deliv
pmo
endosom
pathway
nucleu
inhibit
place
bulki
pmo
nterminu
contrast
pmo
place
cterminu
dmd
skip
activ
restor
close
level
observ
dmd
figur
confirm
cpp
deliveri
optim
cpp
nterminu
block
bulki
substitu
conjug
also
demonstr
high
level
exon
skip
cell
close
singl
figur
conjug
show
exon
skip
dmd
target
intramuscular
deliveri
figur
level
unalt
individu
result
show
conclus
sequestr
one
pmo
target
prevent
action
pmo
target
thu
must
suffici
onoff
equilibrium
establish
target
releas
target
access
import
find
valid
use
bispecif
ppmo
interestingli
bispecif
ppmo
pmo
dmd
conjug
reduc
disulfid
bond
less
activ
stabli
conjug
construct
figur
one
explan
could
due
partial
reduct
disulfid
bond
upon
cell
entri
liber
free
dmd
pmo
bispecif
conjug
deliv
cell
nucleu
howev
note
differ
found
splice
redirect
cell
model
use
either
disulfidelink
stabli
link
pna
contrast
recent
studi
bispecif
phosphorothio
sso
target
mstn
dmd
gene
deliv
use
cation
transfect
reagent
effect
link
cleavabl
disulfid
linker
noncleav
hydrocarbon
linker
differenti
effect
use
cleavabl
disulfid
linkag
probabl
reflect
differ
cell
nuclear
uptak
mechan
sso
deliv
transfect
agent
compar
coval
cpp
deliveri
uncharg
pmo
pna
detail
mechanist
studi
would
need
confirm
note
uptak
dmd
mdx
skelet
muscl
cell
shown
recent
predominantli
caveolaemedi
wherea
cardiomyocyt
uptak
mostli
clathrinmedi
suggest
uptak
rout
also
cell
depend
addit
depend
oligonucleotid
type
deliveri
method
futur
note
effici
exon
skip
pmo
high
exon
skip
pmo
dmd
pmo
therefor
need
optim
improv
effici
target
altern
one
might
prefer
use
combin
pmo
dmd
pmo
target
myostatin
directli
make
bispecif
pmo
rather
target
receptor
thu
second
pmo
need
optim
embark
lengthi
intraven
deliveri
studi
mdx
mice
larger
scale
synthesi
would
need
clearli
studi
need
investig
physiolog
benefit
addit
exon
skip
howev
increas
cell
viabil
human
hepatocyt
cultur
bispecif
conjug
compar
pmo
concentr
mixtur
two
figur
encourag
lower
toxic
maintain
system
deliveri
clinic
import
could
signific
consid
multipl
target
whether
target
differ
exon
gene
two
differ
gene
summari
develop
new
synthet
methodolog
conjug
two
pmo
sso
singl
cpp
shown
effici
target
cell
vivo
two
separ
gene
retain
potenc
sso
work
enabl
system
studi
multipl
sso
target
dmd
also
potenti
neuromuscular
diseas
model
